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Background: Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease that arises
in a multistep fashion through acquisition of several genetic aberrations, subsequently giving rise to a malignant,
clonal expansion of T-lymphoblasts. The aim of the present study was to identify additional as well as cooperative
genetic events in T-ALL.
Methods: A population-based pediatric T-ALL series comprising 47 cases was investigated by SNP array and
deep sequencing analyses of 75 genes, in order to ascertain pathogenetically pertinent aberrations and to
identify cooperative events.
Results: The majority (92%) of cases harbored copy number aberrations/uniparental isodisomies (UPIDs), with a median
of three changes (range 0–11) per case. The genes recurrently deleted comprised CDKN2A, CDKN2B, LEF1, PTEN, RBI, and
STIL. No case had a whole chromosome UPID; in fact, literature data show that this is a rare phenomenon in T-ALL.
However, segmental UPIDs (sUPIDs) were seen in 42% of our cases, with most being sUPID9p that always were
associated with homozygous CDKN2A deletions, with a heterozygous deletion occurring prior to the sUPID9p in
all instances. Among the 75 genes sequenced, 14 (19%) were mutated in 28 (72%) of 39 analyzed cases. The
genes targeted are involved in signaling transduction, epigenetic regulation, and transcription. In some cases,
NOTCH1 mutations were seen in minor subclones and lost at relapse; thus, such mutations can be secondary
events.
Conclusions: Deep sequencing and SNP array analyses of T-ALL revealed lack of wUPIDs, a high proportion of
sUPID9p targeting CDKN2A, NOTCH1 mutations in subclones, and recurrent mutations of genes involved in
signaling transduction, epigenetic regulation, and transcription.
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T-cell acute lymphoblastic leukemia (T-ALL) arises
through a stepwise acquisition of genetic aberrations
that occasionally are important for proper diagnosis and
prognostication as well as for therapeutic decisions [1].
Cytogenetically, approximately half of T-ALL cases
display clonal chromosome aberrations, with the cyto-
genetic and oncogenic hallmark of T-ALL being the
presence of translocations leading to illegitimate rear-
rangements of the T-cell receptor (TCR) loci (mainly
TRA/TRD at 14q11 and TRB at 7q34). Genes targeted,
and hence deregulated, by TCR rearrangements most
often code for transcription factors or proteins involved
in transcriptional complexes, such as the HOXA
(7p15.2), LMO1 (11p15.4), LMO2 (11p13), TAL1 (1p33),Figure 1 Ideogram displaying all copy number alterations (trisomies, del
diagnostic T-ALL samples. Dots and bars represents aberrations <10 and
categorized according to the underlying mechanism: two small (<10 Mb
deletions, one small <10 Mb and one large ≥10 Mb, which together resu
blue bar combined; and sUPID9p and a homozygous deletion were indic
before heterozygous deletions to the right of the chromosome, and sUPI
according to size, with the largest first.TLX1 (10q24.31), and TLX3 (5q35.1) genes [2]. However,
additional abnormalities are required for overt leukemia.
Typical examples include NOTCH1 (9q34.3) and
FBXW7 (4q31.3) mutations and CDKN2A (9p21.3) dele-
tions, which are present in the vast majority of T-ALL
cases [3,4]. In addition, recent array and sequence ana-
lyses have implicated deletions and/or mutations in nu-
merous other genes, with some of the most prevalent
being ETV6 (12p13.2), EZH2 (7q36.1), IL7R (5p13.2),
LEF1 (4q25), NRAS (1p13.2), PHF6 (Xq26.2), PTEN
(10q23.31), RUNX1 (21q22.12), and WT1 (11p13) [5].
Here, we have used single nucleotide polymorphism
(SNP) array and deep sequencing analyses of 75 selected
candidate genes to characterize genetic aberrations in a
consecutive series of pediatric T-ALL.etions, and gains) and sUPIDs identified by SNP array analysis of 40
≥10 Mb, respectively. Homozygous deletions involving 9p21.3 were
) deletions were graphically depicted as a red dot; two heterozygous
lts in a small homozygous deletion were shown as a red dot and a
ated as a red dot and a black bar. Homozygous deletions are placed
Ds are placed before gains to the left. The aberration type is depicted
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SNP array findings
All aberrations found by SNP array analysis are listed in
Additional file 1: Table S1 (using cytogenetic nomencla-
ture) and Additional file 2: Table S2 (with detailed posi-
tions derived from the GRCh37 genome build), and are
summarized graphically in Figure 1. Forty cases could be
successfully analyzed. The vast majority (37/40; 92%)
harbored copy number abnormalities (CNAs), i.e., triso-
mies, deletions, or gains, and/or segmental uniparental
isodisomies (sUPIDs). No monosomies or whole chromo-
some UPIDs (wUPIDs) were detected. In 37 of the investi-
gated cases, karyotypic data were also available. The SNP
array analyses yielded novel information in 35 (95%) of
these. In addition, the SNP arrays could better define the
breakpoints and/or clarify ambiguous unbalanced changes
detected by G-banding analysis in 13 (35%) cases
(Additional file 1: Table S1). All abnormalities seen by
chromosome banding analysis leading to net gain or loss
of genetic material were confirmed by SNP array analysis.
The analyses revealed 128 CNAs, of which 88 (69%)
were <10 Mb and 40 (31%) were ≥10 Mb. The median
number of CNAs per case was 3 (mean 3.3, range 0–10).
Deletions were more common (100/128; 78%) than gains
(28/128; 22%); the latter comprised trisomies (n = 6) and
duplications (n = 22). In addition, 18 sUPIDs were found,
all of which ≥10 Mb. Thus, a total of 146 abnormalities
(CNAs and UPDs combined) were identified, with a
median number of 3 (range 0–11) aberrations per case
(Figure 1 and Additional file 2: Table S2).
Large (≥10 Mb) genomic imbalances
The only trisomies identified involved chromosomes 6,
8, 9, 19, and 21 (Figure 1). The smallest regions of over-
lap of recurrent large duplications were 5p13.1–pter,
7q22.1–31.2, and 13q31.1–qter, whereas the smallest
regions of overlap of recurrent large deletions were
5q21.3–qter, 6q14–16, 7q34–qter (within the TRB locus),
9p11–21.3, and 9p21.2–pter (Figure 1 and Additional
file 1: Table S1).
Small (<10 Mb) genomic imbalances
Six genes were recurrently targeted by deletions: 1)
CDKN2A in 29/40 (72%) cases, of which 28/29 (97%)
were homozygous deletions (either two separate dele-
tions or one deletion in combination with sUPID9p); 2)
CDKN2B (9p21.3) in 25/40 (62%), all of which also in-
volved CDKN2A; 3) STIL (1p33) in 5/40 (12%), all of
which were verified by interphase fluorescence in situ
hybridization (FISH) analysis using the SIL-TAL1 sub-
deletion signal FISH probe (Dako, Glostrup, Denmark);
4) PTEN in 3/40 (8%); 5) LEF1 in 2/40 (5%); and 6) RB1
(13q14.2) in 2/40 (5%). Deletions of PHF6 and upstream
elements of LMO2 were detected in one case each(Figure 1). In four cases (#31, 34, 36, and 37), no dele-
tions involving the TCR genes, representing somatic re-
combination, were detected; however, the finding of
other SNP-identified aberrations and/or high levels of
mutated alleles, as ascertained by deep sequencing, in
these cases proved the presence of leukemic cells in the
investigated samples (Additional file 1: Table S1).sUPIDs
Of the 18 sUPIDs identified in 17 (42%) cases, only 9p was
recurrently targeted (12 cases), including CDKN2A and
CDKN2B in all instances with the minimal overlap span-
ning 9p21.3–pter. All but one of the sUPIDs were terminal
(Figure 1, Additional file 1: Table S1, and Additional file 2:
Table S2). All sUPID9p were associated with homozygous
CDKN2A deletions; CDKN2B was homozygously deleted
in eight (67%) of the 12 cases.Gene mutations
All 75 genes targeted in the 39 cases analyzed could be
successfully deep sequenced (2.1–3.2 million reads/sam-
ple). The mean target coverage varied between 268 times
and 465 times per sample, with 98.3%–99.4% of the tar-
gets having at least 10 times coverage. Conversely, tar-
gets with no coverage ranged from 0.2% to 0.5% per
sample.
A total of 46 mutations were detected among the 39
investigated cases at the time of diagnosis; the median
was 1 mutation per sample (range 0–4) (Additional file 1:
Table S1 and Additional file 3: Table S3). Mutations
were identified in 28 (72%) of the samples. All mutations
were heterozygous, except for one case with a hemizy-
gous mutation of the PHF6 gene at Xq26.2. Of the 46
mutations observed, 35 (76%) were missense, six (13%)
indels, and five (11%) were nonsense.
Details on all mutations are given in Additional file 3:
Table S3. Of the 75 genes sequenced, 14 (19%) were
shown to be mutated at least once: BCL11B at 14q32.2
(n = 1), CREBBP at 16p13.3 (n = 2), DNMT3A at 2p23.3
(n = 1), EZH2 at 7q36.1 (n = 1), FBXW7 at 4q31.3 (n =
12; one case harbored two different mutations), JAK1 at
1p31.3 (n = 1), JAK3 at 19p13.11 (n = 1), NOTCH1 at
9q34.3 (n = 19; two cases carried two and three different
mutations, respectively), NRAS at 1p13.2 (n = 2), PHF6
at Xq26.2 (n = 1), PIK3CA at 3q26.32 (n = 1), PTEN at
10q23.31 (n = 2), SETD2 at 3p21.31 (n = 1), and TCF3 at
19p13.3 (n = 1). Of the 19 NOTCH1 mutations, 17 (89%)
occurred in exons 26–27 (HD domain) and two (11%) in
exon 34 (PEST domain). Identical mutations were found
in three genes: FBXW7 (c.1393C > T in four cases and
c.1513C > T in three cases), NOTCH1 (c.4793G > C in
two cases and c.5033 T > C in three cases), and NRAS
(c.34G > A in two cases).
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samples
Nine of the 47 patients relapsed, and samples from six
of these were analyzed cytogenetically at both diagnosis
and relapse (Figure 2 and Additional file 4: Table S4). At
relapse, three cases (#4, 15, and 21) had additional aber-
rations. In one case (#29), the diagnostic aberration was
not seen at relapse, whereas two (#6 and 10) displayed
identical changes. FISH data on TCR rearrangements
were available for five of the paired samples. In four of
these, the FISH findings did not differ between diagnosis
and relapse. In one case (#15), the diagnostic sample
was positive for a TRA/D rearrangement, whereas the re-
lapses were negative.
SNP array analyses were performed on 11 paired sam-
ples, comprising seven (#4, 6, 10, 15, 21, 35, and 47;
Additional file 4: Table S4) in-house and four (#U1–U4)
external cases, with informative results being obtained in
eight. In two cases (#35 and U4), the aberrations at diag-
nosis and relapse were identical. In three cases (#15, 21,
and U1), all diagnostic abnormalities were present at re-
lapse together with additional changes (clonal evolution).
In three cases (#6, 47, and U2), the diagnostic and
relapse samples not only shared some aberrations but
also harbored distinct aberrations (evolution from a pre-
leukemic/ancestral clone). A total of 13 aberrations were
seen only at relapse; none of these was recurrent. Tar-
geted sequencing analyses were performed on three
paired samples (cases 10, 15, and 47). In two of these
(#10 and 15), the results were concordant between diag-
nosis and relapse. In contrast, case 47 harbored a
NOTCH1 mutation at diagnosis with a variant allele fre-
quency (VAF) of 0.14 (Additional file 3: Table S3); this
mutation was not detected at relapse.
Survival analyses
The probabilities of relapse-free survival (pRFS), event-
free survival (pEFS), and overall survival (pOS) did not
















Figure 2 Summary of the genetic features and the genomic
relationships in the 13 paired diagnostic/relapse samples.counts, and presence/absence of TCR translocations,
STIL deletions, NOTCH1 and/or FBXW7 mutations, or
mutations/deletions of genes involved in epigenetic
regulation or signaling transduction. The pEFS and
pOS (but not pRFS) were significantly lower in girls
than in boys; however, this analysis was based on few
cases (Additional file 5: Table S5).
The presence of CDKN2A deletions was significantly
associated with a high WBC count (median 209 × 109/l
vs. 62 × 109/l; P = 0.013). The pEFS and pRFS did not dif-
fer in relation to CDKN2A status, whereas pOS was sig-
nificantly lower (P = 0.04) for cases with CDKN2A
deletions (Additional file 5: Table S5). Among the 29
cases with loss of CDKN2A, there were no significant
differences between those with (n = 12) and without
sUPID9p (n = 17) as regards age (median 10.9 years vs.
7.0 years; P = 0.18), gender (P = 0.7), or WBC count (me-
dian 242 × 109/l vs. 187 × 109/l; P = 0.25).
Discussion
The rationale for the present study, representing a
truly population-based pediatric T-ALL series com-
prising all 47 cases diagnosed in our catchment area
between 1983 and 2011, was to ascertain whether a
combination of SNP array and large-scale gene muta-
tion analyses could add pathogenetically pertinent
data, in particular as regards cooperative events. Tak-
ing the findings from all these investigatory modalities
into account, it is apparent that T-ALL is character-
ized by multiple genetic changes (Figure 3), in line
with a multistep leukemogenic process [5].
Previous studies using bacterial artificial chromosome or
oligonucleotide arrays have identified recurrent deletions
of several genes in T-ALL, such as BCL11B (14q32.2),
EZH2 (7q36.1), LEF1 (4q25), NF1 (17q11.2), PHF6
(Xq26.2), PTEN (10q23.31), and PTPN2 (18p11.21) [6-12].
Although such investigations have yielded pathogenetically
important information, the drawback of the above-
mentioned techniques is that they do not provide data on
UPIDs. However, surprisingly few SNP array studies of
pediatric T-ALL have been reported [5,13-18], and they
have generally not discussed the frequency and distribu-
tion of UPIDs. Apart from detecting a median of three
CNAs, mainly deletions, per case, similar to other studies
[13,17], and identifying microdeletions of CDKN2A,
CDKN2B, LEF1, PHF6, PTEN, RB1, and STIL, we also ob-
served a total of 18 sUPIDs targeting 6q, 9p, 10q, 13q,
17q, and 19p (Figure 1 and Additional file 1: Table S1).
Interestingly, no wUPIDs were detected. In fact, when
reviewing previous SNP array studies of pediatric T-ALL
with data on UPIDs [13,16,17], only one out of a total of
84 cases had a wUPID at diagnosis. When adding the
present 40 cases, this would translate into a frequency of
0.8% (1/124) of wUPIDs in T-ALL. The reason for the
Figure 3 Overview of all mutations, focal deletions, 6q deletions, and TCR rearrangements identified by large-scale sequencing, SNP array, and
FISH analyses of the pediatric T-ALL cohort.
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simply be due to the fact that the vast majority of T-ALLs
are pseudodiploid. Indeed, wUPIDs appear to be particu-
larly common in aneuploid malignancies, such as hyperha-
ploid inflammatory leiomyosarcoma [19] and near haploid/
low hypodiploid B-cell precursor ALL [20] with chromo-
some doubling as well as in high hyperdiploid BCP ALL
[21,22]. In these cases, the wUPIDs in most instances re-
flect the underlying mechanism of formation.
Except for sUPID9p, the other sUPIDs, involving 6q,
10q, 13q, 17q, and 19p, were non-recurrent. However,
sUPIDs affecting 10q and 17q, overlapping the sUPIDs
identified in our study, have been reported in T-ALL
[13,16]. The prior case with sUPID10q displayed a focalhomozygous PTEN (10q23.31) deletion [13], suggesting
that this could be the pathogenetically important out-
come. In our case (#10; Additional file 1: Table S1),
PTEN was neither deleted nor mutated. As regards
sUPID17q, the gene(s) possibly involved remains to be
identified. In contrast, the target of sUPID9p, detected
in 30% of the present T-ALL cases, is clearly CDKN2A
at 9p21.3. This gene was deleted in 72% of all cases, a
frequency similar to previous studies [4,23,24]. In 86% of
these, the neighboring CDKN2B gene was also deleted.
Interestingly, CDKN2A was homozygously deleted in all 12
cases with sUPID9p, whereas CDKN2B was unaffected in
33% of these cases. Notably, all homozygous CDKN2A de-
letions associated with sUPID9p had identical breakpoints,
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prior to the sUPID.
In one of the investigated cases (U1), the SNP array
analysis revealed a complex rearrangement of 6q, with a
total of 28 breakpoints between 6q14 and 6qter and with
copy number changes oscillating between one and two
copies (Additional file 6: Figure SI), representing chro-
mothripsis [25]. This phenomenon has been described
in numerous tumor types [26], including a few cases of
early T-cell precursor ALL [5]. Notably, the 6q abnor-
mality in case U1 also harbored a larger proximal dele-
tion, involving, among others, the CASP8AP2 gene at
6q15. This gene has been implicated as a prognostic
marker in T-ALL [7,27] and was deleted in all our T-
ALL cases with del(6q).
Most previous mutation analyses of T-ALL have focused
on only one or a few candidate genes, for example ETV6
(12p13.2), FBXW7 (4q31.3), FLT3 (13q12.2), IL7R (5p13.2),
IRS4 (Xq22.3), JAK1 (1p31.3), NOTCH1 (9q34.3), NRAS
(1p13.2), and TP53 (17p13.1). Although such an approach
has been fruitful, it does not provide data on cooperative
mutations in leukemogenesis [3,28-34]. More recently,
studies applying whole genome or exome sequencing have
been forthcoming, reporting an average of approximately
ten protein altering mutations per pediatric T-ALL case
[5,35,36]. In this study, we established a gene panel com-
prising 75 genes previously reported to be mutated in T-
ALL or shown to encode factors of importance in
hematopoiesis. Using this approach, we obtained a mean
sequencing depth of between 268 times and 465 times per
sample, enabling detection of very small subclones.
Of the 39 samples sequenced, 28 (72%) had one or
several mutations, and of the 75 genes, 14 (19%) were
found to be mutated at least once. The genes targeted
can broadly be categorized into one of the three groups:
signaling transduction (JAK1, JAK3, NRAS, PI3KCA, and
PTEN mutations were seen in 15% of cases), epigenetic
regulation (CREBBP, DNMT3A, EZH2, PHF6, and
SETD2; 15%), and transcription (BCL11B, FBXW7,
NOTCH1, and TCF3; 59%) (Figure 3). More than 75% of
the mutations were present in major clones, as ascer-
tained by VAFs above 0.25 (Additional file 3: Table S3).
Because mutations may be misinterpreted as subclonal
due to admixture of non-neoplastic cells, we only con-
sidered mutations with a VAF <0.25 to represent minor
subclones if additional data showed a high proportion of
malignant cells, i.e., if co-occurring mutations or CNAs/
sUPIDs were detected at higher frequencies. Using these
criteria, subclones with FBXW7, NOTCH1, and/or PTEN
were identified in six cases (Additional file 3: Table S3).
NOTCH1 has been suggested to act as an initiating
event in T-ALL [37,38]. However, the present findings,
together with previous studies reporting low-level muta-
tion frequencies of NOTCH1 and relapses of NOTCH1-positive T-ALL being negative for the mutation, as also
seen in our case 47 (Additional file 4: Table S4) [39,40],
show that NOTCH1 mutations also can be secondary
events.
By combining the cytogenetic, FISH, SNP array, and
mutation results in paired diagnostic and relapse sam-
ples, three different evolution patterns emerged: i)
identical clones, ii) clonal evolution, and iii) ancestral
clones (Figure 2 and Additional file 4: Table S4), in line
with prior studies [23,36,40]. In no instance did we
have any evidence for completely distinct clones at re-
lapse. Thus, none of the relapses could be considered a
“second” leukemia, as has been suggested in a few in-
stances of T-ALL relapses [16]. However, the latter
study focused on late relapses, i.e., those occurring
more than 2.5 years after diagnosis, and most of our
cases were early relapses. Quite few additional genetic
changes were present at relapse (Additional file 4: Table
S4), confirming that genomic instability is not a major
feature of T-ALL [15].
Conclusion
The salient findings in the present study were the lack of
wUPIDs, a high proportion of sUPID9p targeting
CDKN2A, NOTCH1 mutations in subclones, and recur-
rent mutations of genes involved in signaling transduc-
tion, epigenetic regulation, and transcription in T-ALL.
Methods
Patients and cytogenetic/FISH analyses
Between 1983 and 2011, 47 children/adolescents (<18 years)
were diagnosed with T-ALL in southern Sweden (Depart-
ments of Pediatric Hematology and Oncology, Lund and
Linköping University Hospitals; Additional file 1: Table S1).
The T-ALL diagnosis was based on immunophenotypic fea-
ture [41]. The male/female ratio was 4.2, median age
9.1 years (range 0.7–17.2 years), and the median WBC
count was 92 × 109/l (range 1.4–768 × 109/l). Mediastinal
and central nervous system involvement was seen in 62%
and 13% of informative cases, respectively (Additional file
7: Table S6). The pRFS, pEFS, and pOS at both 5 and
10 years were 0.815 (0.06), 0.604 (SE 0.07), and 0.665 (SE
0.07), respectively. The basic clinical features did not differ
significantly (chi-square test) from those observed in a
population-based cohort of 285 pediatric Nordic T-ALL pa-
tients previously reported by us [42]. Samples from 44
(94%) of the patients were sent for cytogenetic analysis to
the Department of Clinical Genetics, Lund University Hos-
pital, Sweden. The median number of analyzed metaphases
per case was 17 (range 0–49). All abnormal karyotypes have
been centrally reviewed annually since 1996 by the Swedish
Childhood Leukemia Cytogenetics Group, and five different
treatment protocols were used during this time period by
the Nordic Society for Pediatric Hematology and Oncology
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and −2008 [43,44]. The study was approved by the Regional
Ethical Review Board at Lund University, and informed
consent was obtained according to the Declaration of
Helsinki.
In the present study, interphase FISH analyses using the
TRA/TRD break apart FISH probe (Abbott, Stockholm,
Sweden) and the TRB split signal FISH probe (Dako) were
carried out on 31 diagnostic samples from which cells in
fixative were available. Cutoff values (median +3 SD) for
TRA/TRD and TRB rearrangements, based on analyses of
five normal bone marrow (BM) samples, were 4.9% and
1.1%, respectively. TCR rearrangements, as ascertained by
interphase FISH analysis, were identified in eight (26%) of
the 31 cases investigated; five involved TRA/TRD (#8, 15,
16, 28, and 33) and three TRB (#4, 43, and 45). Six of these
had been detected by G-banding analysis (#8, 16, 28, 33,
43, and 45), whereas two cases (4 and 15) had seemingly
normal karyotypes (Additional file 1: Table S1). The fre-
quency of FISH-identified TCR translocations (26%), with
some of them being cytogenetically cryptic, is in line with
prior reports [45,46].
SNP array analysis—diagnostic samples
DNA was available from 40 of the 44 samples and was
extracted from BM (n = 33) or peripheral blood (n = 7);
in 27/40 (68%) cases, a remission sample could be in-
cluded as a control. The HumanOmni1-Quad Bead-
Chip, containing >1 million markers with a median
marker spacing of 1.5 kb (Illumina, San Diego, CA,
USA), was used. The analyses were performed accord-
ing to the manufacturer’s instructions, and data analysis
was done using the GenomeStudio software 2011.1
(Illumina), extracting probe positions from the GRCh37
genome build (http://www.ensembl.org/Homo_sapiens/
Info/Index). Imbalances seen in remission samples or
overlapping with copy number polymorphisms listed
in the Database of Genomic Variants (http://projects.
tcag.ca/variation/) were excluded from further analysis,
and so were deletions involving the TCR and immuno-
globulin loci because they most likely represent somatic
rearrangements clonotypic for the malignant lymphoid
cells rather than oncogenic events [47].
SNP array analysis—paired diagnostic/relapse samples
Of the 47 patients with T-ALL, nine relapsed (Additional
file 7: Table S6). SNP array analyses could be performed
on diagnostic as well as on relapse samples from seven
of these (Additional file 1: Table S1 and Additional file 4:
Table S4). These samples were analyzed using the
Illumina platform described above. In addition, four
paired diagnostic/relapse T-ALL (cases U1–U4) samples
from the Department of Pediatric Hematology and
Oncology, Norrland University Hospital, Umeå, Sweden,were available for analysis; these were investigated using
the Illumina Humancnv370-Duo BeadChip containing
>370,000 markers, with a median marker spacing of 4.9 kb
(Illumina). The analyses were performed as above with the
exception that the probe positions were extracted from
the NCBI36.1 genome build.
Targeted deep sequencing of 75 genes
A sufficient amount of DNA for large-scale sequencing
was available from 39 diagnostic and three relapse samples
(Additional file 1: Table S1). The DNA quality was evalu-
ated using the NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA) and by visual
inspection of gel images of total genomic DNA. Seventy-
five genes, comprising genes previously reported to be
mutated in T-ALL or to participate in various cellular pro-
cesses in T-cells, such as signaling transduction, epigenetic
regulation, transcription, cell cycle control, cell-cell inter-
action, and DNA repair (Additional file 8: Table S7), were
targeted for capture and deep sequencing. Using the eAr-
ray system (Agilent Technologies, Santa Clara, CA, USA),
a SureSelect capture library was designed to include all
exons and flanking intronic sequences. In addition, 5′UTR
and 3′UTR were added to the selected regions. A total of
15 343 baits, which covered 95% of the target bases, corre-
sponded to a final capture size of 0.5 Mb. After DNA frag-
mentation, which yielded fragments of a median size of
251 bp, sequencing libraries were generated using the Sur-
eSelect post capture protocol for Illumina paired-end
sequencing (Agilent). The samples were sequenced on an
Illumina HiSeq 2000 platform using 100-bp paired-end
reads. The sequences were aligned to the human genome
reference hg 19 (http://hgdownload.cse.ucsc.edu/downloads.
html#human), with the short read alignment program
Burrows-Wheeler Alignment tool [48]. Library prepar-
ation, sequencing, and alignment were performed by
Science for Life Laboratory (SciLifeLab, Solna, Sweden).
After alignment, each sample was evaluated by performing
filtering and variant calling using the Genespring GX
software (Agilent), including removal of duplicates, a
confident score cutoff of 10, base quality of 30, and ignorance
of reference locations under 5/1.
Only variants classified as non-synonymous and not
present as germline SNPs in the dbSNP database were
retained. Of the remaining variants, those fulfilling the
following criteria were considered pathogenetically rele-
vant: i) known cancer-associated mutations listed in
the Ensembl genome browser (http://www.ensembl.org/
index.html) and ii) novel variants that could be confirmed
by Sanger sequencing of diagnostic samples and that were
not present in remission samples. Sanger dideoxy termin-
ator sequencing was performed with primers designed
with Primer3web (http://bioinfo.ut.ee/primer3/); primer
sequences are available upon request. PCR was done using
Karrman et al. Journal of Hematology & Oncology  (2015) 8:42 Page 8 of 9the BigDye® Terminator v1.1 Cycle Sequencing Kit (Ap-
plied Biosystems, Foster City, CA, USA), and the sequen-
cing products were resolved on the 3130 Genetic Analyzer
(Applied Biosystems).
Statistical analyses
The IBM SPSS Statistics for Windows, Version 22
(Armonk, IBM Corp, NY, USA) was used for all statis-
tical analyses. The significance limit for two-sided P
values was set to <0.05. The Mann–Whitney U test
was used to investigate possible correlations between
CDKN2A deletions and age and WBC count. Fisher
exact probability and Mann–Whitney U tests were
used to compare the distribution of gender, age, and
WBC counts between CDKN2A deleted cases with and
without sUPID9p. The pRFS, pEFS, and pOS were cal-
culated using the Kaplan-Meier method, and sub-
groups were compared using the log-rank test. The
following parameters were compared: clinical features
(age, gender, and WBC count), TCR translocations,
SNP array findings, i.e., number of aberrations (CNAs
and sUPIDs combined), and presence/absence of
CDKN2A and STIL deletions, NOTCH1 and/or FBXW7
mutations, and mutations/deletions of genes encoding
proteins involved in epigenetic regulation or signaling
transduction. In the analysis of pEFS, events comprised
induction failure, relapse, second malignant neoplasm,
and death in complete remission 1. In the OS analyses,
death of any cause was the endpoint. Patients in con-
tinuous complete remission 1 were followed up be-
tween 0 and 304 months (median 66 months). The
date of the last follow-up was January 10, 2012.
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